NEW YORK – Under a collaboration and supply agreement announced Wednesday, Kriya Therapeutics gained access to Everads Therapy's platform for delivering its gene therapies to the back of the eye.
Palo Alto, California-based Kriya, which has raised more than $600 million from investors since its founding in 2019, is developing a pipeline of gene therapies for retinal diseases and other conditions. Tel Aviv-based Everads is developing a platform that will allow physicians to non-surgically deliver therapies to the back of the eye via the suprachoroidal space.
"Recent data has shown the promise that the suprachoroidal route of administration has for providing a safe and targeted approach for gene therapy," Everads Executive Chairman and CEO Moshe Weinstein said, adding that the companies are entering into this deal after "a thorough evaluation of [Everads'] technology and its applicability for delivery of gene therapy."
Kriya previously assessed Everads' platform for delivering its own investigational retinal gene therapies in nonhuman primate models. Under the new agreement, Kriya made an undisclosed upfront payment to gain field-based exclusive rights to use Everads' drug delivery platform for certain therapeutic targets including for ophthalmic diseases involving the complement cascade.
Everads retains the ability to use its platform and license it to different firms for other gene therapy and non-gene therapy targets. In the deal, Everads is also entitled to receive development milestone payments from Kriya and royalties on net sales of products using its platform.